Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AGLE
- CUSIP: N/A
- Web: www.aegleabio.com
Capitalization:- Market Cap: $48.29 million
- Outstanding Shares: 13,452,000
Average Prices:- 50 Day Moving Avg: $3.67
- 200 Day Moving Avg: $5.39
- 52 Week Range: $3.28 - $10.34
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.53
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $4.75 million
- Price / Sales: 10.17
- Book Value: $4.25 per share
- Price / Book: 0.84
Profitability:- EBIDTA: ($23,540,000.00)
- Net Margins: -492.49%
- Return on Equity: -35.69%
- Return on Assets: -33.71%
Debt:- Current Ratio: 15.27%
- Quick Ratio: 15.27%
Misc:- Average Volume: 58,298 shs.
- Beta: 4.08
- Short Ratio: 0.97
Frequently Asked Questions for Aeglea BioTherapeutics (NASDAQ:AGLE)
What is Aeglea BioTherapeutics' stock symbol?
Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."
How were Aeglea BioTherapeutics' earnings last quarter?
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) posted its earnings results on Tuesday, May, 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.47). The company earned $0.98 million during the quarter. Aeglea BioTherapeutics had a negative net margin of 492.49% and a negative return on equity of 35.69%. View Aeglea BioTherapeutics' Earnings History.
When will Aeglea BioTherapeutics make its next earnings announcement?
Where is Aeglea BioTherapeutics' stock going? Where will Aeglea BioTherapeutics' stock price be in 2017?
1 brokerages have issued twelve-month price targets for Aeglea BioTherapeutics' shares. Their forecasts range from $19.00 to $19.00. On average, they anticipate Aeglea BioTherapeutics' stock price to reach $19.00 in the next year. View Analyst Ratings for Aeglea BioTherapeutics.
Who are some of Aeglea BioTherapeutics' key competitors?
Some companies that are related to Aeglea BioTherapeutics include Lipocine (LPCN), Zafgen (ZFGN), Applied Genetic Technologies Corporation (AGTC), Proteostasis Therapeutics (PTI), Dicerna Pharmaceuticals (DRNA), Nexvet Biopharma PLC (NVET), ProNAi Therapeutics (SRRA), Ergomed PLC (ERGO), Intec Pharma (NTEC), ImmuPharma PLC (IMM), Flex Pharma (FLKS), Leap Therapeutics (LPTX), Endocyte (ECYT), Verona Pharma Plc (VRP), Xenon Pharmaceuticals (XENE), Rexahn Pharmaceuticals (RNN), Synthetic Biologics (SYN) and Avacta Group Plc (AVCT).
Who are Aeglea BioTherapeutics' key executives?
Aeglea BioTherapeutics' management team includes the folowing people:
- Armen B. Shanafelt Ph.D., Independent Chairman of the Board
- David G. Lowe Ph.D., Co-Founder, President, Chief Executive Officer, Director
- George Georgiou Ph.D., Co-Founder, Director
- Charles N. York II, Chief Financial Officer, Vice President
- Henry L. Hebel, Vice President - Product Development
- Scott W. Rowlinson, Vice President - Research
- Joseph E. Tyler, Vice President - Manufacturing
- Suzanne Bruhn, Director
- Russell J. Cox, Independent Director
- Sandesh Mahatme, Independent Director
When did Aeglea BioTherapeutics IPO?
(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.
How do I buy Aeglea BioTherapeutics stock?
Shares of Aeglea BioTherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeglea BioTherapeutics' stock price today?
One share of Aeglea BioTherapeutics stock can currently be purchased for approximately $3.59.
MarketBeat Community Rating for Aeglea BioTherapeutics (NASDAQ AGLE)MarketBeat's community ratings are surveys of what our community members think about Aeglea BioTherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Aeglea BioTherapeutics (NASDAQ:AGLE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $19.00 (429.25% upside) |
Analysts' Ratings History for Aeglea BioTherapeutics (NASDAQ:AGLE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/10/2016 | BMO Capital Markets | Reiterated Rating | Buy | $19.00 | N/A |  |
| 5/9/2016 | Needham & Company LLC | Initiated Coverage | Buy | $18.00 | N/A | |
| 5/2/2016 | Wells Fargo & Company | Initiated Coverage | Outperform | | N/A | |
(Data available from 7/26/2015 forward)
Earnings History for Aeglea BioTherapeutics (NASDAQ:AGLE)Earnings History by Quarter for Aeglea BioTherapeutics (NASDAQ AGLE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2017 | | ($0.44) | | | | | N/A | |
| 5/9/2017 | 3/31/2017 | ($0.47) | ($0.47) | | $0.98 million | View | N/A | |
| 11/9/2016 | 9/30/2016 | ($0.54) | ($0.47) | | $1.15 million | View | N/A | |
| 8/9/2016 | Q2 2016 | ($0.43) | ($0.46) | | $1.37 million | View | N/A | |
| 5/19/2016 | Q1 2016 | ($0.42) | ($7.10) | | $0.86 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Aeglea BioTherapeutics (NASDAQ:AGLE)Current Year EPS Consensus Estimate: $-2.03 EPS
Next Year EPS Consensus Estimate: $-2.34 EPS
Dividend History for Aeglea BioTherapeutics (NASDAQ:AGLE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aeglea BioTherapeutics (NASDAQ:AGLE)Insider Ownership Percentage: 27.00%
Institutional Ownership Percentage: 31.44%
Insider Trades by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/21/2017 | Orbimed Advisors Llc | Major Shareholder | Buy | 109,300 | $5.16 | $563,988.00 | |
| 4/12/2016 | Anthony Quinn | Director | Buy | 10,000 | $10.00 | $100,000.00 | |
| 4/12/2016 | Bioventures Ltd Novartis | Major Shareholder | Buy | 300,000 | $10.00 | $3,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Aeglea BioTherapeutics (NASDAQ:AGLE)
Latest Headlines for Aeglea BioTherapeutics (NASDAQ:AGLE)
| Source: |
|
| Date | Headline |
|---|
 | Austin biotech company loses CEO as disease treatments work through regulatory process
www.bizjournals.com - July 21 at 10:12 PM |
 | Aeglea BioTherapeutics Announces Leadership Change
finance.yahoo.com - July 20 at 4:33 PM |
| Aeglea Bio shares down 2% after CEO resigns
finance.yahoo.com - July 20 at 4:33 PM |
| Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer
finance.yahoo.com - July 10 at 8:21 PM |
 | ValuEngine Lowers Aeglea BioTherapeutics, Inc. (AGLE) to Strong Sell
www.americanbankingnews.com - July 9 at 12:40 AM |
| -$0.59 EPS Expected for Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) This Quarter
www.americanbankingnews.com - July 4 at 8:10 PM |
| Aeglea BioTherapeutics, Inc. (AGLE) Lifted to Sell at ValuEngine
www.americanbankingnews.com - June 25 at 12:10 AM |
| -$0.59 Earnings Per Share Expected for Aeglea Bio Therapeutics Inc (AGLE) This Quarter
www.americanbankingnews.com - June 8 at 8:40 PM |
 | Aeglea BioTherapeutics (AGLE) Prices 3M Share Offering at $4.10/Sh
www.streetinsider.com - June 8 at 1:00 AM |
| Aeglea BioTherapeutics Prices Public Offering of Common Stock
finance.yahoo.com - June 6 at 10:32 AM |
| Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - June 5 at 6:36 PM |
| Aeglea Bio Therapeutics Inc (AGLE) Downgraded by TheStreet to D+
www.americanbankingnews.com - June 1 at 2:22 PM |
| Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer
finance.yahoo.com - May 25 at 3:45 PM |
| Achaogen's Plazomicin Gets Breakthrough Therapy Designation
finance.yahoo.com - May 24 at 3:24 PM |
| Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
finance.yahoo.com - May 23 at 3:27 PM |
| Brokerages Expect Aeglea Bio Therapeutics Inc (AGLE) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - May 12 at 4:02 PM |
| ETFs with exposure to Aeglea Biotherapeutics, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 8:41 PM |
| Aeglea Bio Therapeutics Inc (AGLE) Issues Earnings Results
www.americanbankingnews.com - May 10 at 9:14 PM |
| Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 3:30 PM |
 | Aeglea reports 1Q loss
marketbeat.com - May 9 at 9:41 AM |
| Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 9:25 AM |
| ETFs with exposure to Aeglea Biotherapeutics, Inc. : April 28, 2017
finance.yahoo.com - April 28 at 4:01 PM |
| Zacks: Brokerages Anticipate Aeglea Bio Therapeutics Inc (AGLE) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - April 21 at 10:48 PM |
| New Strong Buy Stocks for April 13th
finance.yahoo.com - April 13 at 3:37 PM |
| Aeglea Bio Therapeutics Inc (AGLE) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - April 12 at 9:33 PM |
 | New Strong Buy Stocks for April 12th
www.zacks.com - April 12 at 12:03 PM |
| Austin biotech startup with $7M more in funding wants to beef up cancer-fighting drugs
www.bizjournals.com - April 10 at 3:22 PM |
| Short Interest in Aeglea Bio Therapeutics Inc (AGLE) Drops By 39.0%
www.americanbankingnews.com - April 8 at 1:20 PM |
| Analysts Expect Aeglea Bio Therapeutics Inc (AGLE) to Announce ($1.15) Earnings Per Share
www.americanbankingnews.com - April 6 at 8:04 AM |
| Edited Transcript of AGLE earnings conference call or presentation 23-Mar-17 8:30pm GMT
finance.yahoo.com - March 30 at 3:48 PM |
| Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
finance.yahoo.com - March 29 at 8:32 PM |
| AEGLEA BIOTHERAPEUTICS, INC. Financials
finance.yahoo.com - March 29 at 3:29 PM |
| Aeglea BioTherapeutics to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 8:24 PM |
| Q4 2016 Aeglea Bio Therapeutics Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 23 at 11:29 PM |
 | Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting
us.rd.yahoo.com - March 23 at 11:29 PM |
| Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 23 at 11:29 PM |
| Aeglea Bio Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
us.rd.yahoo.com - March 23 at 11:29 PM |
| 8:03 am Aeglea BioTherapeutics will present topline data from a Phase 1 open-label study evaluating the safety and tolerability of its lead product candidate, AEB1102, for patients with Arginase I deficiency at the ACMG Annual Meeting
finance.yahoo.com - March 23 at 3:35 PM |
| Aeglea Bio Therapeutics Inc (AGLE) to Release Earnings on Thursday
www.americanbankingnews.com - March 22 at 7:34 AM |
| Aeglea BioTherapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results on Thursday, March 23
finance.yahoo.com - March 17 at 4:05 PM |
 | Aeglea Biotherapeutics: Interesting Early-Stage Enzyme Therapy
seekingalpha.com - March 9 at 3:27 PM |
| AEGLEA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 7 at 6:31 AM |
| Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism
finance.yahoo.com - February 28 at 8:22 AM |
| Aeglea Biotherapeutics (AGLE) Looks Good: Stock Jumps 7%
finance.yahoo.com - February 23 at 3:24 PM |
| Aeglea BioTherapeutics (AGLE) Appoints Suzanne Bruhn to Board of Directors
www.streetinsider.com - February 18 at 9:30 AM |
| Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors
finance.yahoo.com - February 16 at 8:27 PM |
| Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors
finance.yahoo.com - February 16 at 8:27 PM |
| Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors
finance.yahoo.com - February 16 at 8:27 PM |
| AEGLEA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 16 at 8:27 PM |
| AEGLEA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 16 at 8:27 PM |
Aeglea BioTherapeutics (AGLE) Chart for Wednesday, July, 26, 2017
